Natera stock gets Medicare coverage boost for Signatera in HCC
Published on 11/04/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMedicare broadens Signatera access
- Medicare coverage now includes serial Signatera testing for eligible early-stage liver cancer patients under surveillance after treatment.
- A 125-patient real-world study supported the decision and compared Signatera with alpha-fetoprotein.
- Natera will publish third-quarter results after the market closes on November 5, 2026.
Natera announced on Tuesday, November 3, 2026, that Medicare coverage for its Signatera molecular residual disease test now includes serial testing for patients with early-stage hepatocellular carcinoma who have no post-surgical evidence of disease. The company described the decision as an expansion of access in the surveillance setting.
The announcement was reported by Business Wire. Natera said the coverage decision was supported by a real-world study of 125 patients published in JCO Precision Oncology. In that study, Signatera showed 83 percent sensitivity versus 42 percent for alpha-fetoprotein, with specificity of 100 percent.
Coverage expands the oncology case
The study also found that Signatera identified recurrence up to 16.5 months ahead of imaging, with a median lead time of 7.9 months, compared with 2.2 months for alpha-fetoprotein. The figures support the test's role in recurrence surveillance, but the coverage announcement does not provide a revenue forecast or quantify the commercial contribution.
Natera stock traded at 333.15 euros on Lang & Schwarz at 4:32 p.m. CET on Wednesday, November 4, 2026. The quote places the market's attention on the new coverage milestone and the company's next operating update.
real-time quote of Natera stock is available alongside the latest trading information.
Natera will release its third-quarter results after the market closes on Thursday, November 5, 2026, and will hold its conference call at 4:30 p.m. Eastern Time. Investors are likely to focus on testing volumes, oncology adoption and management's outlook.
The S&P 500 provides the broader market backdrop for US-listed Natera stock.
More news and analyses on Natera stock cover the company's diagnostics pipeline and upcoming results.
Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Business: Precision medicine and molecular diagnostics
- Quote: 333.15 euros on Lang & Schwarz, November 4, 2026, 4:32 p.m. CET
- Next event: Third-quarter results on November 5, 2026, after the market close
